TriSalus Life Sciences Inc

TLSI

4.390USD

-0.060-1.35%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

TriSalus Life Sciences Inc's Score

Industry at a Glance

Industry Ranking

195 / 407

Overall Ranking

352 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

11.583

Target Price

+160.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

TriSalus Life Sciences Inc Highlights

StrengthsRisks

TriSalus Life Sciences, Inc. is an oncology focused medical technology business providing drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. Its two Food and Drug Administration (FDA) cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. Additionally, the Company is exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 137.39% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 29.43M.

Fairly Valued

The company’s latest PE is -3.80, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 8.63M shares, increasing 25.39% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 814.39K shares of this stock.

The company's current financial score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.21M, representing a year-over-year increase of 52.27%, while its net profit experienced a year-over-year increase of 75.38%.

Score

Industry at a Glance

Previous score

8.50

Change

0



Financials

6.78

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.63

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 6.25, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.80, which is -100.00% below the recent high of 0.00 and -43.18% above the recent low of -5.44.

Score

Industry at a Glance

Previous score

6.25

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 195/407

No Data

The company’s current earnings forecast score is 8.29, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for TriSalus Life Sciences Inc is 11.00, with a high of 16.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.29

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

There is no price momentum score for this company; the Biotechnology & Medical Research industry's average is 6.45.

Score

Industry at a Glance

Previous score

0.00

Change

0

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 17.30%, representing a quarter-over-quarter decrease of 73.04%. The largest institutional shareholder is The Vanguard, holding a total of 814.39K shares, representing 1.63% of shares outstanding, with 7.25% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Frankenius Equity AB

6.99M

+12.18%

Utmost Group PLC

1.98M

-1.02%

Pallotta (James Joseph)

2.15M

+19.50%

Nantahala Capital Management, LLC

2.00M

--

Wahlstrom (Mats)

1.62M

+24.91%

HW Investment Partners LLC

1.37M

--

AWM Investment Company, Inc.

1.25M

--

Sands Point LLC

1.13M

--

Gilder Gagnon Howe & Co. LLC

1.09M

+32.10%

Hicks (Kerry R)

979.77K

+6.59%



1

2



The company’s current risk assessment score is 2.60, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

TriSalus Life Sciences Inc

TLSI

5.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

MDGL

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Dynavax Technologies Corp

DVAX

8.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment